Tag Archives | cancer vaccines immunotherapy

Bio Investor Forum #2: T-Cell Therapies and Cancer Targets

Genetically Modified T-cells: Gene Therapy Is Back! Here are some quick notes and an overview of the companies at Bio: Immuno-Oncology  is one of the hottest new areas of biopharmaceutical development and on October 7  BIO presented a Therapeutic Session on “T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets”. […]

Continue Reading 0

ASCO Oncology Stocks: Recap and Scoreboard- AGIO, MDVN, SGEN Winners

High Profile Biotechnology Companies with ASCO Presence Investors and traders waited toward the end of the ASCO Annual Meeting week to buy their favorite stocks. The biotech sector overall was boosted after the close of the meeting after a brief sell-off on June 2 and 3. Most biopharmaceutical stocks peaked in late February so ASCO […]

Continue Reading

Innovation Drives Market Gains in Biopharmaceuticals

This article was published in Genetic Engineering News in the section “Wall Street Biobeat” on April 1, 2011. Monoclonal antibody therapies remain the dominant technology with immunotherapy and stem cell therapies on the horizon. GEN | Articles: Innovations Continue to Drive Market Gains Emerging Technologies in Biomedicine-Continuing Series Published in Genetic Engineering News April 1 […]

Continue Reading

Amgen(AMGN) To Buy Biovex For Cancer Vaccine Technology

Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and  Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone payments as much as $525M. The Biovex lead product OncoVex, an oncolytic vaccine, is in a Phase III multinational study for metastatic melanoma. A second study […]

Continue Reading